Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Wall Street in Fives - Must Read Lists for Friday » 16:25
07/30/21
07/30
16:25
07/30/21
16:25
AMZN

Amazon.com

$3,328.01 /

-271.3 (-7.54%)

, PINS

Pinterest

$58.92 /

-13 (-18.08%)

, PG

Procter & Gamble

$142.28 /

+2.95 (+2.12%)

, CVX

Chevron

$101.77 /

-0.77 (-0.75%)

, XOM

Exxon Mobil

$57.57 /

-1.34 (-2.27%)

, ABBV

AbbVie

$116.25 /

-2.64 (-2.22%)

, GILD

Gilead

$68.29 /

-1.57 (-2.25%)

, TMUS

T-Mobile

$144.03 /

-0.56 (-0.39%)

, ZEN

Zendesk

$130.66 /

-20.06 (-13.31%)

, LBTYA

Liberty Global

$26.83 /

+1.07 (+4.15%)

, LBTYK

Liberty Global

$26.86 /

+1.175 (+4.57%)

, MDLZ

Mondelez

$63.26 /

-0.07 (-0.11%)

, NOK

Nokia

$6.08 /

+0.04 (+0.66%)

, PFPT

Proofpoint

$174.66 /

+0.035 (+0.02%)

, DUOL

Duolingo

$140.08 /

+3.13 (+2.29%)

, NVDA

Nvidia

$194.89 /

-1.72 (-0.87%)

, UBER

Uber

$43.47 /

-1.22 (-2.73%)

, PFE

Pfizer

$42.81 /

+ (+0.00%)

, WMT

Walmart

$142.56 /

+0.33 (+0.23%)

, BNTX

BioNTech

$328.33 /

+15.76 (+5.04%)

, TEAM

Atlassian

$325.18 /

+58.385 (+21.88%)

, KLAC

KLA Corp.

$348.21 /

+28.945 (+9.07%)

, MAXR

Maxar Technologies

$36.27 /

+1.26 (+3.60%)

, UPWK

Upwork

$51.79 /

-5.67 (-9.87%)

, SAVA

Cassava Sciences

$69.56 /

-33.85 (-32.73%)

Get caught up quickly on…

ShowHide Related Items >><<
ZEN Zendesk
$130.66 /

-20.06 (-13.31%)

XOM Exxon Mobil
$57.57 /

-1.34 (-2.27%)

WMT Walmart
$142.56 /

+0.33 (+0.23%)

UPWK Upwork
$51.79 /

-5.67 (-9.87%)

UBER Uber
$43.47 /

-1.22 (-2.73%)

TMUS T-Mobile
$144.03 /

-0.56 (-0.39%)

TEAM Atlassian
$325.18 /

+58.385 (+21.88%)

SAVA Cassava Sciences
$69.56 /

-33.85 (-32.73%)

PINS Pinterest
$58.92 /

-13 (-18.08%)

PG Procter & Gamble
$142.28 /

+2.95 (+2.12%)

PFPT Proofpoint
$174.66 /

+0.035 (+0.02%)

PFE Pfizer
$42.81 /

+ (+0.00%)

NVDA Nvidia
$194.89 /

-1.72 (-0.87%)

NOK Nokia
$6.08 /

+0.04 (+0.66%)

MDLZ Mondelez
$63.26 /

-0.07 (-0.11%)

MAXR Maxar Technologies
$36.27 /

+1.26 (+3.60%)

LBTYA Liberty Global
$26.83 /

+1.07 (+4.15%)

KLAC KLA Corp.
$348.21 /

+28.945 (+9.07%)

GILD Gilead
$68.29 /

-1.57 (-2.25%)

CVX Chevron
$101.77 /

-0.77 (-0.75%)

BNTX BioNTech
$328.33 /

+15.76 (+5.04%)

AMZN Amazon.com
$3,328.01 /

-271.3 (-7.54%)

ABBV AbbVie
$116.25 /

-2.64 (-2.22%)

AMZN Amazon.com
$3,328.01 /

-271.3 (-7.54%)

07/30/21 JPMorgan
Amazon.com price target lowered to $4,100 from $4,600 at JPMorgan
07/30/21 Cowen
Amazon.com price target lowered to $4400 from $4600 at Cowen
07/30/21 UBS
Amazon.com price target lowered to $4,020 from $4,350 at UBS
07/30/21 Oppenheimer
Amazon.com price target lowered to $4,200 from $4,400 at Oppenheimer
PINS Pinterest
$58.92 /

-13 (-18.08%)

07/30/21
Fly Intel: Top five analyst downgrades
07/30/21 MKM Partners
Pinterest price target lowered to $74 from $90 at MKM Partners
07/30/21 Morgan Stanley
Pinterest price target lowered to $77 from $83 at Morgan Stanley
07/30/21 Wedbush
Pinterest price target lowered to $70 from $91 at Wedbush
PG Procter & Gamble
$142.28 /

+2.95 (+2.12%)

06/23/21 UBS
Procter & Gamble initiated with a Neutral at UBS
04/21/21
Fly Intel: Top five analyst downgrades
04/21/21 Roth Capital
PureCycle Technologies initiated with a Buy at Roth Capital
04/21/21 Citi
Procter & Gamble downgraded to Neutral from Buy at Citi
CVX Chevron
$101.77 /

-0.77 (-0.75%)

07/23/21 Piper Sandler
Chevron price target raised to $137 from $126 at Piper Sandler
07/22/21
Fly Intel: Top five analyst downgrades
07/22/21 Redburn
Chevron upgraded to Buy from Neutral at Redburn
07/22/21 HSBC
Chevron downgraded to Hold from Buy at HSBC
XOM Exxon Mobil
$57.57 /

-1.34 (-2.27%)

07/23/21 Piper Sandler
Exxon Mobil price target raised to $69 from $63 at Piper Sandler
07/22/21 HSBC
Exxon Mobil price target lowered to $57 from $65 at HSBC
07/12/21
Fly Intel: Top five analyst initiations
07/12/21 BMO Capital
Exxon Mobil initiated with a Market Perform at BMO Capital
ABBV AbbVie
$116.25 /

-2.64 (-2.22%)

07/30/21 Piper Sandler
AbbVie growth lever being held 'hostage' by FDA, says Piper Sandler
07/26/21 Truist
AbbVie assumed with a Buy at Truist
07/26/21 Truist
AbbVie assumed with a Buy at Truist
07/02/21
Fly Intel: Top five analyst initiations
GILD Gilead
$68.29 /

-1.57 (-2.25%)

07/30/21 BMO Capital
Gilead price target raised to $72 from $67 at BMO Capital
07/30/21 RBC Capital
Gilead price target raised to $84 from $81 at RBC Capital
06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
TMUS T-Mobile
$144.03 /

-0.56 (-0.39%)

07/30/21
Fly Intel: Top five analyst upgrades
07/30/21 Truist
T-Mobile price target raised to $175 from $150 at Truist
07/30/21 RBC Capital
T-Mobile upgraded to Outperform from Sector Perform at RBC Capital
07/30/21 RBC Capital
T-Mobile upgraded to Outperform from Sector Perform at RBC Capital
ZEN Zendesk
$130.66 /

-20.06 (-13.31%)

05/27/21
Fly Intel: Top five analyst upgrades
05/27/21 UBS
Zendesk upgraded to Buy from Neutral at UBS
04/30/21 Piper Sandler
Zendesk price target raised to $186 from $180 at Piper Sandler
04/22/21 Wolfe Research
Zendesk initiated with an Outperform at Wolfe Research
LBTYA Liberty Global
$26.83 /

+1.07 (+4.15%)

07/29/21 Deutsche Bank
Liberty Global named short-term investment idea at Deutsche Bank
06/23/21 JPMorgan
Liberty Global resumed with an Overweight at JPMorgan
05/07/21 Barclays
Liberty Global price target raised to $35 from $32 at Barclays
05/06/21 Pivotal Research
Liberty Global 'moving in the right direction,' says Pivotal Research
LBTYK Liberty Global
$26.86 /

+1.175 (+4.57%)

09/29/20 Pivotal Research
Liberty Global price target raised to $40 from $30 at Pivotal Research
MDLZ Mondelez
$63.26 /

-0.07 (-0.11%)

07/30/21 Goldman Sachs
Mondelez downgraded to Buy from Conviction Buy at Goldman Sachs
07/19/21 Morgan Stanley
Morgan Stanley equity strategist upgrades Consumer Staples, downgrades Materials
07/19/21 Deutsche Bank
Mondelez price target raised to $71 from $70 at Deutsche Bank
NOK Nokia
$6.08 /

+0.04 (+0.66%)

07/30/21 Barclays
Nokia price target raised to EUR 5 from EUR 4.50 at Barclays
07/30/21 Cowen
Cowen upgrades Nokia to Outperform on favorable demand, turnaround progress
07/30/21 Cowen
Nokia upgraded to Outperform from Market Perform at Cowen
07/14/21
Fly Intel: Top five analyst upgrades
PFPT Proofpoint
$174.66 /

+0.035 (+0.02%)

07/30/21 JMP Securities
Proofpoint downgraded to Market Perform from Outperform at JMP Securities
05/24/21 Baird
Proofpoint downgraded to Neutral from Outperform at Baird
04/27/21 Truist
Proofpoint downgraded to Hold from Buy at Truist
DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

NVDA Nvidia
$194.89 /

-1.72 (-0.87%)

07/23/21 Jefferies
Intel price target lowered to $52 from $54 at Jefferies
07/23/21 Argus
Nvidia price target raised to $230 from $175 at Argus
07/22/21 Citi
Nvidia price target raised to $223 from $180 at Citi
07/21/21 Oppenheimer
Nvidia price target lowered to $235 from $925 at Oppenheimer
UBER Uber
$43.47 /

-1.22 (-2.73%)

07/22/21 Stifel
Acquisition of Transplace expands Uber Freight's capabilities, says Stifel
07/21/21 DA Davidson
HyreCar initiated with a Buy at DA Davidson
07/01/21 Cowen
Uber target raised to $80 on rising mobility users at Cowen
07/01/21 Arete
Uber upgraded to Neutral from Sell at Arete
PFE Pfizer
$42.81 /

+ (+0.00%)

07/30/21 Mizuho
Pfizer price target raised to $43 from $42 at Mizuho
07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/23/21 BMO Capital
Arvinas price target raised to $111 from $101 at BMO Capital
WMT Walmart
$142.56 /

+0.33 (+0.23%)

07/12/21 Morgan Stanley
Walmart+ membership 'treading water' in 9M-10M range, says Morgan Stanley
07/08/21 Craig-Hallum
Craig-Hallum bullish on Revolution Acceleration Acquisition, initiates with Buy
06/24/21 BofA
Comcast not pressured to make any imminent acquisition, says BofA
06/24/21 Citi
Walmart valuation multiple attractive and below peers, says Citi
BNTX BioNTech
$328.33 /

+15.76 (+5.04%)

07/19/21 Wolfe Research
BioNTech assumed with an Outperform at Wolfe Research
06/16/21
Fly Intel: Top five analyst downgrades
06/16/21 Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
TEAM Atlassian
$325.18 /

+58.385 (+21.88%)

07/30/21 Canaccord
Atlassian price target raised to $325 from $275 at Canaccord
07/30/21 Truist
Atlassian price target raised to $270 from $200 at Truist
07/30/21 Mizuho
Atlassian price target raised to $370 from $310 at Mizuho
07/30/21 Piper Sandler
Atlassian price target raised to $308 from $259 at Piper Sandler
KLAC KLA Corp.
$348.21 /

+28.945 (+9.07%)

07/30/21 Cowen
KLA Corp. price target raised to $355 from $335 at Cowen
07/30/21 Needham
KLA Corp. upgraded to Buy from Hold at Needham
07/30/21 Deutsche Bank
KLA Corp. price target raised to $400 from $375 at Deutsche Bank
MAXR Maxar Technologies
$36.27 /

+1.26 (+3.60%)

07/15/21 Morgan Stanley
Maxar Technologies initiated with an Overweight at Morgan Stanley
07/14/21 Baird
Baird starts Maxar Technologies at Neutral, cautious ahead of Legion launch
07/14/21 Baird
Maxar Technologies initiated with a Neutral at Baird
06/22/21 BofA
BofA starts Maxar Technologies at Neutral, sees runway along with risks
UPWK Upwork
$51.79 /

-5.67 (-9.87%)

07/30/21 MKM Partners
Upwork price target raised to $65 from $58 at MKM Partners
07/01/21 BTIG
Upwork price target raised to $76 from $65 at BTIG
05/05/21 BTIG
Upwork price target lowered to $65 from $75 at BTIG
02/25/21 Citi
Upwork price target raised to $75 from $48 at Citi
SAVA Cassava Sciences
$69.56 /

-33.85 (-32.73%)

07/30/21 B. Riley
Cassava Sciences data represents 'home run scenario,' says B. Riley
07/20/21 H.C. Wainwright
Cassava Sciences price target raised to $124 from $97 at H.C. Wainwright
07/15/21
Fly Intel: Top five analyst downgrades
07/15/21 Cantor Fitzgerald
Cassava Sciences downgraded to Neutral from Overweight at Cantor Fitzgerald
ZEN Zendesk
$130.66 /

-20.06 (-13.31%)

XOM Exxon Mobil
$57.57 /

-1.34 (-2.27%)

WMT Walmart
$142.56 /

+0.33 (+0.23%)

UPWK Upwork
$51.79 /

-5.67 (-9.87%)

UBER Uber
$43.47 /

-1.22 (-2.73%)

TMUS T-Mobile
$144.03 /

-0.56 (-0.39%)

TEAM Atlassian
$325.18 /

+58.385 (+21.88%)

SAVA Cassava Sciences
$69.56 /

-33.85 (-32.73%)

PINS Pinterest
$58.92 /

-13 (-18.08%)

PG Procter & Gamble
$142.28 /

+2.95 (+2.12%)

PFPT Proofpoint
$174.66 /

+0.035 (+0.02%)

PFE Pfizer
$42.81 /

+ (+0.00%)

NVDA Nvidia
$194.89 /

-1.72 (-0.87%)

NOK Nokia
$6.08 /

+0.04 (+0.66%)

MDLZ Mondelez
$63.26 /

-0.07 (-0.11%)

MAXR Maxar Technologies
$36.27 /

+1.26 (+3.60%)

LBTYA Liberty Global
$26.83 /

+1.07 (+4.15%)

KLAC KLA Corp.
$348.21 /

+28.945 (+9.07%)

GILD Gilead
$68.29 /

-1.57 (-2.25%)

CVX Chevron
$101.77 /

-0.77 (-0.75%)

BNTX BioNTech
$328.33 /

+15.76 (+5.04%)

AMZN Amazon.com
$3,328.01 /

-271.3 (-7.54%)

ABBV AbbVie
$116.25 /

-2.64 (-2.22%)

  • 29
    Jul
  • 28
    Jul
  • 18
    Mar
  • 08
    Jan
  • 13
    Nov
XOM Exxon Mobil
$57.57 /

-1.34 (-2.27%)

WMT Walmart
$142.56 /

+0.33 (+0.23%)

UPWK Upwork
$51.79 /

-5.67 (-9.87%)

UBER Uber
$43.47 /

-1.22 (-2.73%)

TMUS T-Mobile
$144.03 /

-0.56 (-0.39%)

SAVA Cassava Sciences
$69.56 /

-33.85 (-32.73%)

PINS Pinterest
$58.92 /

-13 (-18.08%)

PG Procter & Gamble
$142.28 /

+2.95 (+2.12%)

PFPT Proofpoint
$174.66 /

+0.035 (+0.02%)

PFE Pfizer
$42.81 /

+ (+0.00%)

NVDA Nvidia
$194.89 /

-1.72 (-0.87%)

NOK Nokia
$6.08 /

+0.04 (+0.66%)

MDLZ Mondelez
$63.26 /

-0.07 (-0.11%)

MAXR Maxar Technologies
$36.27 /

+1.26 (+3.60%)

GILD Gilead
$68.29 /

-1.57 (-2.25%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

CVX Chevron
$101.77 /

-0.77 (-0.75%)

BNTX BioNTech
$328.33 /

+15.76 (+5.04%)

AMZN Amazon.com
$3,328.01 /

-271.3 (-7.54%)

ABBV AbbVie
$116.25 /

-2.64 (-2.22%)

ZEN Zendesk
$130.66 /

-20.06 (-13.31%)

WMT Walmart
$142.56 /

+0.33 (+0.23%)

UPWK Upwork
$51.79 /

-5.67 (-9.87%)

UBER Uber
$43.47 /

-1.22 (-2.73%)

TMUS T-Mobile
$144.03 /

-0.56 (-0.39%)

TEAM Atlassian
$325.18 /

+58.385 (+21.88%)

PINS Pinterest
$58.92 /

-13 (-18.08%)

PG Procter & Gamble
$142.28 /

+2.95 (+2.12%)

PFPT Proofpoint
$174.66 /

+0.035 (+0.02%)

PFE Pfizer
$42.81 /

+ (+0.00%)

NVDA Nvidia
$194.89 /

-1.72 (-0.87%)

NOK Nokia
$6.08 /

+0.04 (+0.66%)

MDLZ Mondelez
$63.26 /

-0.07 (-0.11%)

MAXR Maxar Technologies
$36.27 /

+1.26 (+3.60%)

GILD Gilead
$68.29 /

-1.57 (-2.25%)

DUOL Duolingo
$140.08 /

+3.13 (+2.29%)

CVX Chevron
$101.77 /

-0.77 (-0.75%)

BNTX BioNTech
$328.33 /

+15.76 (+5.04%)

AMZN Amazon.com
$3,328.01 /

-271.3 (-7.54%)

ABBV AbbVie
$116.25 /

-2.64 (-2.22%)

XOM Exxon Mobil
$57.57 /

-1.34 (-2.27%)

WMT Walmart
$142.56 /

+0.33 (+0.23%)

UPWK Upwork
$51.79 /

-5.67 (-9.87%)

UBER Uber
$43.47 /

-1.22 (-2.73%)

TMUS T-Mobile
$144.03 /

-0.56 (-0.39%)

TEAM Atlassian
$325.18 /

+58.385 (+21.88%)

SAVA Cassava Sciences
$69.56 /

-33.85 (-32.73%)

PINS Pinterest
$58.92 /

-13 (-18.08%)

PG Procter & Gamble
$142.28 /

+2.95 (+2.12%)

PFE Pfizer
$42.81 /

+ (+0.00%)

NVDA Nvidia
$194.89 /

-1.72 (-0.87%)

NOK Nokia
$6.08 /

+0.04 (+0.66%)

MDLZ Mondelez
$63.26 /

-0.07 (-0.11%)

MAXR Maxar Technologies
$36.27 /

+1.26 (+3.60%)

KLAC KLA Corp.
$348.21 /

+28.945 (+9.07%)

GILD Gilead
$68.29 /

-1.57 (-2.25%)

CVX Chevron
$101.77 /

-0.77 (-0.75%)

BNTX BioNTech
$328.33 /

+15.76 (+5.04%)

AMZN Amazon.com
$3,328.01 /

-271.3 (-7.54%)

ABBV AbbVie
$116.25 /

-2.64 (-2.22%)

Recommendations
Sanofi price target raised to EUR 100 from EUR 93 at JPMorgan » 14:38
07/30/21
07/30
14:38
07/30/21
14:38
SNY

Sanofi

$51.55 /

+0.03 (+0.06%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Sanofi to EUR 100 from EUR 93 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
SNY Sanofi
$51.55 /

+0.03 (+0.06%)

SNY Sanofi
$51.55 /

+0.03 (+0.06%)

07/29/21 H.C. Wainwright
Regeneron price target raised to $729 from $703 at H.C. Wainwright
07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
SNY Sanofi
$51.55 /

+0.03 (+0.06%)

SNY Sanofi
$51.55 /

+0.03 (+0.06%)

SNY Sanofi
$51.55 /

+0.03 (+0.06%)

Thursday
Recommendations
Regeneron price target raised to $729 from $703 at H.C. Wainwright » 12:58
07/29/21
07/29
12:58
07/29/21
12:58
REGN

Regeneron

$585.00 /

-1.51 (-0.26%)

, SNY

Sanofi

$51.32 /

-0.74 (-1.42%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Michael King raised the firm's price target on Regeneron Pharmaceuticals (REGN) to $729 from $703 and keeps a Buy rating on the shares after the company and Sanofi (SNY) announced Dupixent met all key primary and secondary endpoints in the Phase 3 trial for chronic spontaneous urticaria. The data continues to support Dupixent's "well-established" safety profile, King tells investors in a research note. The analyst updated his model to reflect the increased probability of success for Dupixent.

ShowHide Related Items >><<
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

Options
Unusually active option classes on open July 29th » 09:40
07/29/21
07/29
09:40
07/29/21
09:40
LODE

Comstock Mining

$3.01 /

+ (+0.00%)

, ING

ING Groep

$12.76 /

+ (+0.00%)

, VXRT

Vaxart

$8.20 /

+ (+0.00%)

, ZM

Zoom Video

$369.42 /

+0.06 (+0.02%)

, NOK

Nokia

$5.81 /

+ (+0.00%)

, HPQ

HP Inc.

$28.48 /

+ (+0.00%)

, BUD

AB InBev

$68.62 /

+ (+0.00%)

, MGM

MGM Resorts

$38.40 /

+ (+0.00%)

, UBER

Uber

$46.14 /

+0.01 (+0.02%)

Unusual total active…

Unusual total active option classes on open include: Comstock Mining (LODE), ING Group (ING), Royal Dutch Shell (RDS/A), Vaxart (VXRT), Zoom Video Communications (ZM), Nokia (NOK), HP Inc. (HPQ), Anheuser Busch (BUD), MGM Resorts (MGM), and Uber (UBER).

ShowHide Related Items >><<
ZM Zoom Video
$369.42 /

+0.06 (+0.02%)

VXRT Vaxart
$8.20 /

+ (+0.00%)

UBER Uber
$46.14 /

+0.01 (+0.02%)

NOK Nokia
$5.81 /

+ (+0.00%)

MGM MGM Resorts
$38.40 /

+ (+0.00%)

LODE Comstock Mining
$3.01 /

+ (+0.00%)

ING ING Groep
$12.76 /

+ (+0.00%)

HPQ HP Inc.
$28.48 /

+ (+0.00%)

BUD AB InBev
$68.62 /

+ (+0.00%)

LODE Comstock Mining
$3.01 /

+ (+0.00%)

ING ING Groep
$12.76 /

+ (+0.00%)

07/09/21 UBS
ING Groep price target raised to EUR 12 from EUR 11.70 at UBS
07/08/21 JPMorgan
ING Groep price target raised to EUR 12.40 from EUR 12 at JPMorgan
06/22/21 Kepler Cheuvreux
Kepler Cheuvreux downgrades European banks to Neutral from Overweight
06/04/21 Barclays
ING Groep downgraded to Underweight from Equal Weight at Barclays
VXRT Vaxart
$8.20 /

+ (+0.00%)

06/30/21
Fly Intel: Top five analyst downgrades
06/30/21 B. Riley
B. Riley downgraded Vaxart to Neutral on 'riskier development path'
06/29/21 B. Riley
Vaxart downgraded to Neutral from Buy at B. Riley
06/24/21 Jefferies
Vaxart initiated with a Buy at Jefferies
ZM Zoom Video
$369.42 /

+0.06 (+0.02%)

07/29/21 KeyBanc
KeyBanc upgrades Zoom with $428 target on 'future hybrid work state'
07/29/21 KeyBanc
Zoom Video upgraded to Overweight from Sector Weight at KeyBanc
07/28/21 Piper Sandler
Five9 downgraded to Neutral from Overweight at Piper Sandler
07/27/21 Jefferies
Five9 downgraded to Hold from Buy at Jefferies
NOK Nokia
$5.81 /

+ (+0.00%)

07/14/21
Fly Intel: Top five analyst upgrades
07/14/21 JPMorgan
JPMorgan upgrades Nokia on 'more room to run' for mobile turnaround
07/13/21 JPMorgan
Nokia upgraded to Overweight from Neutral at JPMorgan
07/12/21 Barclays
Nokia price target raised to EUR 4.50 from EUR 4.25 at Barclays
HPQ HP Inc.
$28.48 /

+ (+0.00%)

07/02/21 Bernstein
HP plus Xerox 'consolidation math compelling,' says Bernstein
05/28/21 Morgan Stanley
HP Inc. post-earnings pullback a buying opportunity, says Morgan Stanley
05/28/21 Citi
Citi says HP is not at peak, reiterates Buy rating
05/28/21 Deutsche Bank
HP Inc. price target raised to $32 from $30 at Deutsche Bank
BUD AB InBev
$68.62 /

+ (+0.00%)

07/15/21 Barclays
AB InBev price target raised to EUR 75 from EUR 74 at Barclays
07/07/21 Deutsche Bank
AB InBev price target raised to EUR 62 from EUR 59 at Deutsche Bank
07/07/21 JPMorgan
AB InBev price target raised to EUR 65 from EUR 55 at JPMorgan
07/07/21 UBS
AB InBev price target raised to EUR 63 from EUR 61 at UBS
MGM MGM Resorts
$38.40 /

+ (+0.00%)

07/28/21
Fly Intel: Top five analyst upgrades
07/28/21 Goldman Sachs
MGM Resorts upgraded to Neutral from Sell at Goldman Sachs
06/24/21
Fly Intel: Top five analyst upgrades
06/24/21 Deutsche Bank
Deutsche upgrades MGM Resorts to Buy on margin upside potential
UBER Uber
$46.14 /

+0.01 (+0.02%)

07/22/21 Stifel
Acquisition of Transplace expands Uber Freight's capabilities, says Stifel
07/21/21 DA Davidson
HyreCar initiated with a Buy at DA Davidson
07/01/21 Cowen
Uber target raised to $80 on rising mobility users at Cowen
07/01/21 Arete
Uber upgraded to Neutral from Sell at Arete
ZM Zoom Video
$369.42 /

+0.06 (+0.02%)

VXRT Vaxart
$8.20 /

+ (+0.00%)

UBER Uber
$46.14 /

+0.01 (+0.02%)

NOK Nokia
$5.81 /

+ (+0.00%)

MGM MGM Resorts
$38.40 /

+ (+0.00%)

ING ING Groep
$12.76 /

+ (+0.00%)

HPQ HP Inc.
$28.48 /

+ (+0.00%)

BUD AB InBev
$68.62 /

+ (+0.00%)

  • 29
    Jul
  • 13
    Jan
  • 08
    Jan
ZM Zoom Video
$369.42 /

+0.06 (+0.02%)

VXRT Vaxart
$8.20 /

+ (+0.00%)

UBER Uber
$46.14 /

+0.01 (+0.02%)

NOK Nokia
$5.81 /

+ (+0.00%)

MGM MGM Resorts
$38.40 /

+ (+0.00%)

LODE Comstock Mining
$3.01 /

+ (+0.00%)

ING ING Groep
$12.76 /

+ (+0.00%)

HPQ HP Inc.
$28.48 /

+ (+0.00%)

BUD AB InBev
$68.62 /

+ (+0.00%)

ZM Zoom Video
$369.42 /

+0.06 (+0.02%)

VXRT Vaxart
$8.20 /

+ (+0.00%)

UBER Uber
$46.14 /

+0.01 (+0.02%)

NOK Nokia
$5.81 /

+ (+0.00%)

MGM MGM Resorts
$38.40 /

+ (+0.00%)

LODE Comstock Mining
$3.01 /

+ (+0.00%)

HPQ HP Inc.
$28.48 /

+ (+0.00%)

BUD AB InBev
$68.62 /

+ (+0.00%)

ZM Zoom Video
$369.42 /

+0.06 (+0.02%)

VXRT Vaxart
$8.20 /

+ (+0.00%)

UBER Uber
$46.14 /

+0.01 (+0.02%)

NOK Nokia
$5.81 /

+ (+0.00%)

MGM MGM Resorts
$38.40 /

+ (+0.00%)

LODE Comstock Mining
$3.01 /

+ (+0.00%)

HPQ HP Inc.
$28.48 /

+ (+0.00%)

BUD AB InBev
$68.62 /

+ (+0.00%)

Hot Stocks
Vaxart reports boosting immune response in subjects with Vaxart vaccine » 08:26
07/29/21
07/29
08:26
07/29/21
08:26
VXRT

Vaxart

$8.20 /

+0.15 (+1.86%)

Vaxart has shown for the…

Vaxart has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier. The data came from Vaxart's 12-subject Phase 1b blinded study evaluating the ability of its norovirus vaccine to boost immunogenicity. Study participants were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019 and were vaccinated again between February and April 2021. All seven participants who had been previously immunized with the oral norovirus vaccine elicited a similar broad range of immune responses to norovirus as the five subjects that had not received a prior oral vaccine dose. Serum antibody blocking titer 50,a surrogate neutralizing antibody measurement, increased in both previously vaccinated and unvaccinated subjects by similar amounts. Antibodysecreting B cell responses to norovirus VP1 measuredseven days post-boost were no different thanthose in subjects receiving the vaccine for the first time. Serum IgG and IgA antibody responses were significantly elevated 29 days post-boost immunization, with no difference in titer between subjects that had received a prior oral norovirus vaccineand those who had not previously been vaccinated.

ShowHide Related Items >><<
VXRT Vaxart
$8.20 /

+0.15 (+1.86%)

VXRT Vaxart
$8.20 /

+0.15 (+1.86%)

06/30/21
Fly Intel: Top five analyst downgrades
06/30/21 B. Riley
B. Riley downgraded Vaxart to Neutral on 'riskier development path'
06/29/21 B. Riley
Vaxart downgraded to Neutral from Buy at B. Riley
06/24/21 Jefferies
Vaxart initiated with a Buy at Jefferies
VXRT Vaxart
$8.20 /

+0.15 (+1.86%)

VXRT Vaxart
$8.20 /

+0.15 (+1.86%)

VXRT Vaxart
$8.20 /

+0.15 (+1.86%)

VXRT Vaxart
$8.20 /

+0.15 (+1.86%)

Hot Stocks
Sanofi now sees FY21 business EPS up around 12% at CER » 06:35
07/29/21
07/29
06:35
07/29/21
06:35
SNY

Sanofi

$52.06 /

+0.505 (+0.98%)

Sanofi now expects 2021…

Sanofi now expects 2021 business EPS to grow around 12% at CER, barring unforeseen major adverse events. Applying average July 2021 exchange rates, the currency impact on 2021 business EPS is estimated to be between -4% to -5%.

ShowHide Related Items >><<
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

Earnings
Sanofi reports Q2 business EPS EUR1.38, up 16.4% at CER » 06:35
07/29/21
07/29
06:35
07/29/21
06:35
SNY

Sanofi

$52.06 /

+0.505 (+0.98%)

Q2 sales grew double…

Q2 sales grew double digit to EUR 8.7 billion, up 12.4% at CER, mainly driven by Dupixent and Vaccines. CEO Paul Hudson commented: "The Sanofi business momentum has accelerated in the second quarter, delivering strong financial results driven by our core growth drivers Dupixent and Vaccines. We continue to deliver on our Play to Win strategy, and our second quarter performance gives us confidence in Sanofi's growth trajectory for this year. Consequently, we are raising our full-year EPS guidance to around 12%. Significant progress was made across several clinical and regulatory milestones and in June, we formed the Sanofi mRNA vaccines Center of Excellence with the aim to lead the field in this next chapter of vaccine innovation. We are well on our way making Sanofi more representative of communities we serve, executing on our Diversity and Inclusion strategy and creating a work environment where our people can bring their best selves to transform the practice of medicine."

ShowHide Related Items >><<
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

Hot Stocks
Regeneron, Sanofi announce Dupixent trial met primary and secondary endpoints » 05:53
07/29/21
07/29
05:53
07/29/21
05:53
REGN

Regeneron

$586.33 /

+5.33 (+0.92%)

, SNY

Sanofi

$52.06 /

+0.505 (+0.98%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced a pivotal Phase 3 trial evaluating Dupixent in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, met its primary and all key secondary endpoints at 24 weeks. Adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives for biologic-naive patients, compared to antihistamines alone in Study A, the first of two trials of the LIBERTY-CUPID clinical program. In the trial, adding Dupixent to standard-of-care antihistamines nearly doubled the reduction in itch and urticaria activity compared to standard-of-care alone (placebo) with continuous improvement out to 24 weeks. Patients experienced a 63% reduction in itch severity with Dupixent versus 35% with placebo, as measured by a 0-21 point itch severity scale, the primary endpoint in the U.S.; 65% reduction in urticaria activity severity with Dupixent versus 37% with placebo, as measured by a 0-42 point urticaria activity scale, the secondary endpoint in the U.S. The trial demonstrated safety results similar to the known safety profile of Dupixent in its approved indications. For the 24-week treatment period, the occurrence of treatment emergent adverse events were generally similar between the Dupixent and placebo groups. The most common adverse events were injection site reactions. The potential use of Dupixent in CSU and EoE is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.

ShowHide Related Items >><<
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

Wednesday
Hot Stocks
NY to require all state employees be vaccinated or get tested regularly » 14:15
07/28/21
07/28
14:15
07/28/21
14:15
SPX

S&P 500

/

+

, SPY

SPDR S&P 500 ETF Trust

$438.09 /

-0.9 (-0.21%)

, PFE

Pfizer

$43.44 /

+1.38 (+3.28%)

, BNTX

BioNTech

$303.29 /

+19.205 (+6.76%)

, MRNA

Moderna

$343.45 /

+15.065 (+4.59%)

, JNJ

Johnson & Johnson

$172.63 /

-0.015 (-0.01%)

New York Governor Andrew…

New York Governor Andrew Cuomo said the state will mandate that all state employees either be vaccinated for COVID-19 or get tested regularly. "We are working with the state unions to implement this program quickly & fairly," Cuomo said. "Will take effect by Labor Day." Companies with COVID-19 vaccines approved for distribution in the U.S. include Pfizer (PFE) and BioNTech (BNTX), Moderna (MRNA), and Johnson & Johnson (JNJ). Reference Link

ShowHide Related Items >><<
SPX S&P 500
/

+

PFE Pfizer
$43.44 /

+1.38 (+3.28%)

MRNA Moderna
$343.45 /

+15.065 (+4.59%)

JNJ Johnson & Johnson
$172.63 /

-0.015 (-0.01%)

BNTX BioNTech
$303.29 /

+19.205 (+6.76%)

SPX S&P 500
/

+

03/15/21 Morgan Stanley
Morgan Stanley equity strategist downgrades small cap stocks
03/12/21
On The Fly: Weekly technical notes for S&P 500
01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
SPY SPDR S&P 500 ETF Trust
$438.09 /

-0.9 (-0.21%)

PFE Pfizer
$43.44 /

+1.38 (+3.28%)

07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/23/21 BMO Capital
Arvinas price target raised to $111 from $101 at BMO Capital
07/23/21 Citi
Arvinas price target raised to $153 from $118 at Citi
BNTX BioNTech
$303.29 /

+19.205 (+6.76%)

07/19/21 Wolfe Research
BioNTech assumed with an Outperform at Wolfe Research
06/16/21
Fly Intel: Top five analyst downgrades
06/16/21 Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
MRNA Moderna
$343.45 /

+15.065 (+4.59%)

07/15/21 Jefferies
Moderna price target raised to $250 from $170 at Jefferies
07/07/21 Piper Sandler
Moderna could 'revolutionize' flu vaccine market, says Piper Sandler
06/29/21 Wells Fargo
Moderna vaccine demonstrates activity against key variants, says Wells Fargo
06/29/21 Goldman Sachs
Goldman continues to anticipate clinical need for booster vaccines
JNJ Johnson & Johnson
$172.63 /

-0.015 (-0.01%)

07/08/21 Stifel
Vor Biopharma, Janssen collaboration benefits both parties, says Stifel
07/02/21 Cantor Fitzgerald
J&J vaccine shows 'strong' activist against Delta, says Cantor Fitzgerald
06/28/21 Cantor Fitzgerald
J&J opioid settlement removes share overhang, says Cantor Fitzgerald
06/22/21 JPMorgan
Opioid settlement would be best case for manufacturers, says JPMorgan
SPX S&P 500
/

+

PFE Pfizer
$43.44 /

+1.38 (+3.28%)

MRNA Moderna
$343.45 /

+15.065 (+4.59%)

JNJ Johnson & Johnson
$172.63 /

-0.015 (-0.01%)

BNTX BioNTech
$303.29 /

+19.205 (+6.76%)

SPX S&P 500
/

+

PFE Pfizer
$43.44 /

+1.38 (+3.28%)

MRNA Moderna
$343.45 /

+15.065 (+4.59%)

BNTX BioNTech
$303.29 /

+19.205 (+6.76%)

SPX S&P 500
/

+

PFE Pfizer
$43.44 /

+1.38 (+3.28%)

MRNA Moderna
$343.45 /

+15.065 (+4.59%)

JNJ Johnson & Johnson
$172.63 /

-0.015 (-0.01%)

BNTX BioNTech
$303.29 /

+19.205 (+6.76%)

SPX S&P 500
/

+

PFE Pfizer
$43.44 /

+1.38 (+3.28%)

MRNA Moderna
$343.45 /

+15.065 (+4.59%)

JNJ Johnson & Johnson
$172.63 /

-0.015 (-0.01%)

BNTX BioNTech
$303.29 /

+19.205 (+6.76%)

SPY SPDR S&P 500 ETF Trust
$438.09 /

-0.9 (-0.21%)

SPX S&P 500
/

+

Hot Stocks
Pfizer vaccine efficacy gradually declines over six months, study says » 12:54
07/28/21
07/28
12:54
07/28/21
12:54
PFE

Pfizer

$43.71 /

+1.65 (+3.92%)

, BNTX

BioNTech

$298.80 /

+14.715 (+5.18%)

Pfizer (PFE) and…

Pfizer (PFE) and BioNTech's (BNTX) Covid vaccine's efficacy was 91% through up to six months of follow-up, among evaluable participants and irrespective of previous SARS-CoV-2 infection, a new study published in medRxiv says. Vaccine efficacy of 86%-100% was seen across countries and in populations with diverse characteristics of age, sex, race/ethnicity, and Covid-19 risk factors in participants without evidence of previous SARS-CoV-2 infection. With up to six months of follow-up and "despite a gradually declining trend in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing COVID-19," the study concludes. Reference Link

ShowHide Related Items >><<
PFE Pfizer
$43.71 /

+1.65 (+3.92%)

BNTX BioNTech
$298.80 /

+14.715 (+5.18%)

PFE Pfizer
$43.71 /

+1.65 (+3.92%)

07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/26/21 Truist
Pfizer assumed with a Buy at Truist
07/23/21 BMO Capital
Arvinas price target raised to $111 from $101 at BMO Capital
07/23/21 Citi
Arvinas price target raised to $153 from $118 at Citi
BNTX BioNTech
$298.80 /

+14.715 (+5.18%)

07/19/21 Wolfe Research
BioNTech assumed with an Outperform at Wolfe Research
06/16/21
Fly Intel: Top five analyst downgrades
06/16/21 Redburn
BioNTech downgraded to Sell from Neutral at Redburn
05/18/21
Fly Intel: Top five analyst initiations
PFE Pfizer
$43.71 /

+1.65 (+3.92%)

BNTX BioNTech
$298.80 /

+14.715 (+5.18%)

PFE Pfizer
$43.71 /

+1.65 (+3.92%)

BNTX BioNTech
$298.80 /

+14.715 (+5.18%)

PFE Pfizer
$43.71 /

+1.65 (+3.92%)

BNTX BioNTech
$298.80 /

+14.715 (+5.18%)

PFE Pfizer
$43.71 /

+1.65 (+3.92%)

BNTX BioNTech
$298.80 /

+14.715 (+5.18%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.